Welcome to our dedicated page for ELITE PHARMACEUTICALS /NV/ SEC filings (Ticker: ELTP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ELITE PHARMACEUTICALS /NV/'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ELITE PHARMACEUTICALS /NV/'s regulatory disclosures and financial reporting.
Elite Pharmaceuticals, Inc. reported financial results for the first quarter of fiscal year 2027, ended June 30, 2026. Consolidated revenues were $32.4 million, a decrease of $7.9 million or about 19.5% from the same quarter of the prior fiscal year, which had been its largest quarterly revenue. Income from operations was $7.5 million, down $14.2 million or about 65%, primarily due to lower margins on sales of the company’s generic Vyvanse product line as competitive market adjustments weighed more heavily on this quarter.
The company stated that, despite the year-over-year decline, first-quarter results are in line with the three preceding quarters. Net income attributable to common shareholders was $5.9 million. Management will discuss the results and provide a business update on a conference call scheduled for August 14, 2026 at 11:30 AM EDT.
Elite Pharmaceuticals, Inc. reported for the quarter ended June 30, 2026 revenue of $32.4 million, down from $40.2 million a year earlier, as increased competition, including on its Lisdexamfetamine line, reduced average net pricing. Cost of manufacturing rose to $18.8 million, cutting gross margin to 42% from 68% and reducing income from operations to $7.5 million from $21.7 million.
Despite weaker operating results, the company posted net income of $5.9 million, compared with a $5.9 million loss in the prior-year quarter, helped by a much smaller impact from warrant fair-value adjustments and higher interest income. Operating cash flow was strong at $10.1 million, and cash and restricted cash increased to $39.4 million. The balance sheet shows total assets of $139.7 million, liabilities of $34.8 million, and shareholders’ equity of $104.8 million, with working capital of $84.0 million.
Elite continues to expand its generic portfolio, launching methadone tablets in April 2026 and a generic Requip XL (ropinirole extended-release) in July 2026, and it filed an anticoagulant ANDA and reported positive pivotal bioequivalence results for an anticonvulsant generic. A patent suit by Purdue Pharma relating to Elite’s generic OxyContin ANDA was dismissed by court order in June 2026. Revenue remains concentrated, with two customers representing 73% of sales.
Elite Pharmaceuticals, Inc. filed an amended current report to correct the previously stated conference-call deadlines from November to August. The company plans to release financial results for the first quarter of fiscal year 2027, covering the period ended June 30, 2026, on August 13, 2026. Management will then host a conference call on August 14, 2026 at 11:30 AM EDT to discuss financial and operating results and provide a corporate update. Investors can join via domestic dial-in 1-800-346-7359 or international 1-973-528-0008 using conference number 98840, and are invited to submit general and financial questions by specified email deadlines prior to the call. An audio replay will be available online.
Elite Pharmaceuticals, Inc. reported that it will release financial results for the first quarter of fiscal year 2027, covering the period ended June 30, 2026, on August 13, 2026. Management will then host a live conference call on August 14, 2026 at 11:30 AM EDT to discuss financial and operating results and provide a corporate update.
Investors can join the call via domestic dial-in 1-800-346-7359 or international dial-in 1-973-528-0008, using conference number 98840. Stockholders are invited to submit general and financial questions in advance to dianne@elitepharma.com by the deadlines provided in the notice.
Elite Pharmaceuticals, Inc. reported the commercial launch of its generic version of Requip XL (Ropinirole Extended-Release Tablets USP) in the United States. The product is offered in 2 mg, 4 mg, 6 mg, 8 mg and 12 mg strengths and is marketed and sold under the Elite Laboratories, Inc. label.
Ropinirole is a non-ergoline dopamine agonist used to treat Parkinson’s disease. According to IQVIA, the branded product and its equivalents generated $10 million in total U.S. sales for the twelve months ending June 2026, providing an indication of the market size for this therapy class.
Elite Pharmaceuticals reported sharply improved results for the fiscal year ended March 31, 2026. Consolidated revenues reached $148.9 million, an increase of $64.8 million, or about 77%, over the prior year. Income from operations was $49.1 million, up $29.5 million, or roughly 151%.
The company attributed the stronger operating income mainly to a full-year contribution from its Lisdexamfetamine product, revenues from Oxycodone Acetaminophen tablets launched during the year, and Naltrexone and Phentermine tablets sold exclusively under the Elite label, along with broad growth across its product lines.
Management will discuss these year-end 2026 results and recent business developments on a conference call scheduled for June 30, 2026 at 11:30 AM EDT, with domestic and international dial-in numbers and an audio replay link provided.
Elite Pharmaceuticals, Inc. provides an overview of its business in generic and specialty oral drugs in its annual report for the year ended March 31, 2026. The company now operates as a single ANDA-based segment after pausing NDA development, and reported ANDA segment revenue of $148.9 million, up from $84.0 million in the prior year.
Elite highlights a broad portfolio of solid oral dose generics, including CNS stimulants, bariatric, cardiovascular, pain and other therapies, all manufactured at its cGMP and DEA-registered Northvale, New Jersey facility. Recent launches include Methotrexate Tablets, several opioid combination pain products, Lisdex Capsules for ADHD, Oxy APAP Tablets, and Methadone Tablets, many acquired via a June 2024 asset purchase from Nostrum Laboratories.
The company notes expiration of its long-running Precision Dose license in September 2025, termination of a Prasco non-exclusive license in March 2025, and first international shipments of amphetamine tablets under a Dexcel agreement in July 2025. Development of its SequestOx abuse-deterrent opioid candidate remains paused, and a related patent and Loxapine Capsules were impaired after reassessing expected cash flows. As of June 27, 2026, Elite had a public float valued at approximately $534 million and 1,077,196,442 common shares outstanding, supported by a workforce of 65 employees.
Elite Pharmaceuticals, Inc. filed an 8-K to announce timing for its fiscal year 2026 results and a related conference call. The company will release financial results for the year ended March 31, 2026 on June 29, 2026.
Management will host a live conference call on June 30, 2026 at 11:30 AM EDT to discuss financial and operating results and provide a corporate update. Investors can join using domestic dial-in 1-800-346-7359 or international 1-973-528-0008 with conference number 98840, and are invited to email questions in advance.
Elite Pharmaceuticals reported positive results from a pivotal bioequivalence study for an undisclosed generic anticonvulsant. The study showed the generic is bioequivalent to the branded drug, meaning it delivers the same amount of active ingredient into the bloodstream under the test conditions.
The trial used an open-label, randomized, two-period crossover design in healthy adults under fasting conditions, which is a standard approach for bioequivalence work. Elite is now compiling the data to file an Abbreviated New Drug Application with the US Food and Drug Administration, the key regulatory step needed to market the product in the United States.
IQVIA reported combined branded and generic product sales for this market of $840 million for the twelve months ending April 2026, highlighting the commercial scale of the opportunity if Elite’s generic ultimately secures approval and market access.
Elite Pharmaceuticals, Inc. filed a Current Report to highlight that it has submitted an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration for a generic drug in the anticoagulant class. The branded reference product generated $26 billion in sales for the twelve months ending March 2026, according to IQVIA, and currently has no generic competition.
The brand still has unexpired patents and regulatory exclusivities listed in the FDA’s Orange Book, so any future generic launch would depend on FDA approval and successfully addressing these protections. The press release with additional details is furnished as an exhibit and is treated as furnished, not filed, under securities laws.